Benzinga | Dec 16, 2021 07:17AM EST

uniQure Announces Clinical Update On First Patients In Phase I/II Clinical Trial Of AMT-130 Gene Therapy For The Treatment Of Huntington's Disease

~ Treatment was well tolerated with no significant safety issues

related to AMT-130 in first two treated patients through one year of follow-up ~

~ Neurofilament Light Chain (NfL) rose as expected immediately following surgery and

returned to baseline in treated patients ~

~ A total of 19 patient procedures have been performed in the U.S. Phase I/II clinical trial,

with higher-dose cohort enrollment expected to be completed by mid-2022 ~

~ Screening initiated in European open-label Phase I/II study ~

~ Conference call today at 8:30 a.m. ET ~